- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03272113
SKIP-IT Smoking Cessation in Pregnancy (SKIP-IT)
Promoting Smoking Cessation During Pregnancy: a Combined Feasibility and Pilot Trial of a Theory-based Intervention Using Narrative, Images and Embedded Behaviour Change Techniques, Delivered Via Text-messaging
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Smoking during pregnancy carries serious risks to mother and infant health. More babies whose mothers smoke are stillborn or die within the first year of life. Smoking during pregnancy results in increased rates of intrauterine growth retardation, preterm birth, and babies' longer-term risk of developing heart disease and diabetes. Pregnant women who smoke are more likely to experience miscarriage, placental abruption, pregnancy-induced hypertension and later conditions such as lung cancer and heart disease.
Reduction in smoking in pregnancy has been a long standing health policy target however there is limited evidence of effectiveness of many smoking cessation interventions and their uptake is generally low. We have developed, and carried out initial testing of an intervention to support smoking cessation in pregnant women using narrative, story-telling delivered via automated text-messages. The intervention aims to alter women's perceptions of risk, social norms, outcomes and self-efficacy using three key elements. 1. a narrative story of a fictional young pregnant woman 'Megan' trying to stop smoking by overcoming a series of commonplace barriers. 2) images showing the size of their fetus and its stage of development 3) an interactive 'help' function to receive a supportive, tailored response. Behaviour change techniques for smoking cessation in pregnancy are embedded in the intervention.
A randomised controlled trial is required to test the effectiveness of the intervention in reducing smoking in pregnancy. The aim of this study is to investigate the feasibility and likelihood of success of the narrative and image-based intervention for smoking cessation in pregnant women. If successful the intervention will be tested in a full-scale (Phase III) multi centre randomised controlled trial.
Objectives:
- To assess acceptability and willingness to be randomised to the narrative and image based intervention or usual care.
- To assess and compare the feasibility of recruitment strategies, the level of participants' retention in the study and engagement with the intervention.
- To assess the acceptability and likely impact of the intervention among pregnant smokers.
- To estimate the required sample size for a full trial.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Ayr, Storbritannia
- NHS Ayrshire and Arran
-
Perth, Storbritannia
- NHS Tayside
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women 16 years of age or over,
- Live within the catchment areas of study sites,
- Up to and including 14 weeks of pregnancy,
- Current smoker,
- Own or regularly use a mobile phone with media capability,
- Understand written English,
- Able to give informed consent.
Exclusion Criteria:
- Women who do not currently smoke,
- Live outside the catchment areas of study sites,
- Over 14 weeks of pregnancy,
- Do not use or have access to a mobile phone with media capability,
- Cannot understand written English,
- Not able to give informed consent,
- Already enrolled in an alternative formal smoking cessation trial at the time of referral to the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Control
Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support. Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week. |
|
Eksperimentell: Intervention
Women will receive usual care as described above plus the SKIP-IT intervention
|
A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Recruitment rate
Tidsramme: 23 months
|
Progression to a full trial will require recruitment ≥50% of women who give permission to have their details passed to the research team (i.e.
those who express initial interest in the study).
|
23 months
|
Drop out rate
Tidsramme: 23 months
|
Progression to a full trial will require <30% dropout
|
23 months
|
Direction of effect
Tidsramme: 23 months
|
Progression to a full trial will require direction of effect on smoking cessation rate in favour of the intervention.
|
23 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Engagement
Tidsramme: 23 months
|
Engagement in the intervention will be assessed using data captured by the computer system which monitors the text message responses.
|
23 months
|
Acceptability
Tidsramme: 23 months
|
Acceptability of the intervention will be assessed in short interviews conducted with intervention group participants at the follow-up points
|
23 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Smoking cessation outcomes
Tidsramme: At each subsequent data collection time-point (4 weeks post-randomisation, 36 weeks of pregnancy, 6-7 weeks post due-date, 12-13 weeks post due-date)
|
|
At each subsequent data collection time-point (4 weeks post-randomisation, 36 weeks of pregnancy, 6-7 weeks post due-date, 12-13 weeks post due-date)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- RMS2119
- HIPS/16/4 (Annet stipend/finansieringsnummer: Scottish Government Chief Scientist Office)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på SKIP-IT
-
Karolinska InstitutetRekruttering
-
University of WashingtonNational Institute of Nursing Research (NINR)FullførtAstma | SøvnforstyrrelserForente stater
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)FullførtKlinisk beslutningstaking | KunnskapsoverføringCanada
-
Philips Clinical & Medical Affairs GlobalFullførtPerifer arteriesykdom | Kritisk iskemi i lemmerØsterrike
-
University of Texas at AustinBaylor College of Medicine; University of Kansas Medical CenterFullført
-
Oslo University HospitalCentre for Appearance Research, University of the West of England, UKPåmelding etter invitasjonBrannsår | Leppe og ganespalte | Kraniofaciale abnormiteter | Hudtilstand | Andre forhold som fører til en synlig forskjellNorge
-
ShireFullført
-
ShireFullførtHunters syndromSpania, Forente stater, Canada, Storbritannia, Frankrike, Australia, Mexico
-
Integro TheranosticsRekrutteringBrystkreft | DCIS | Invasivt kanalkarsinom i brystetForente stater
-
Benjamin Van Voorhees, MD, MPHNorthwestern University; NorthShore University HealthSystem; Advocate Health... og andre samarbeidspartnereFullførtDyp depresjon | Depressive episoderForente stater